This technology created from the use of nuclear magnetic resonance is called LIPOSCALE and is already being applied in many clinical studies on different pathologies.
A new predictive test “will allow better treatment, better estimation and greater precision of our patients’ cardiovascular risk,” said Dr. Ángel Díaz Rodríguez, coordinator of the Working Group of Lipids of the Spanish Society of Primary Care (SEMERGEN).
Dr. Díaz Rodríguez participated in the Mesa ‘Importance of the size of lipoproteins in the screening of cardiovascular risk: LIPOSCALE’, held in the framework of SEMERGEN Cardiovascular Conferences (Santander, from May 19 to 21, 2016), session in Which was also attended by doctors Nuria Amigó Grau and Vicente Pallarés Carratalá. This technology created from the use of nuclear magnetic resonance is called LIPOSCALE and is already being applied in many clinical studies on different pathologies.
